1、 BARANISKIN A,BIRKENKAMP-DEMTRODER K,MAGHNOUJ A,et al.MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL[J]. Carcinogenesis,2012,33(4):732-739. BARANISKIN A,BIRKENKAMP-DEMTRODER K,MAGHNOUJ A,et al.MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL[J]. Carcinogenesis,2012,33(4):732-739.
2、 LI K C,YU S H,ZHUGE B Z.PIK3CG single nucleotide polymorphisms are associated with poor responsiveness to clopidogrel and increased risk of ischemia in patients with coronary heart disease[J]. Medicine (Baltimore),2017,96(36):e7566. LI K C,YU S H,ZHUGE B Z.PIK3CG single nucleotide polymorphisms are associated with poor responsiveness to clopidogrel and increased risk of ischemia in patients with coronary heart disease[J]. Medicine (Baltimore),2017,96(36):e7566.
3、 ZOU A,MAGEE N,DENG F,et al.Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis[J]. J Biol Chem,2018,293(22):8656-8671. ZOU A,MAGEE N,DENG F,et al.Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis[J]. J Biol Chem,2018,293(22):8656-8671.
4、 WRUCK W,ADJAYE J.Meta-analysis reveals up-regulation of cholesterol processes in non-alcoholic and down-regulation in alcoholic fatty liver disease[J]. World J Hepatol,2017,9(8):443-454. WRUCK W,ADJAYE J.Meta-analysis reveals up-regulation of cholesterol processes in non-alcoholic and down-regulation in alcoholic fatty liver disease[J]. World J Hepatol,2017,9(8):443-454.
5、 ABDOLLAHI H,ZAMANIAN AZODI M,HATAMI B.Protein interaction mapping interpretation of none alcoholic fatty liver disease model of rats after fat diet feeding[J]. Gastroenterol Hepatol Bed Bench,2017,10(Suppl1):S146-S153. ABDOLLAHI H,ZAMANIAN AZODI M,HATAMI B.Protein interaction mapping interpretation of none alcoholic fatty liver disease model of rats after fat diet feeding[J]. Gastroenterol Hepatol Bed Bench,2017,10(Suppl1):S146-S153.
6、 YANG X,FU Y,HU F,et al.PIK3R3 regulates PPARalpha expression to stimulate fatty acid beta-oxidation and decrease hepatosteatosis[J]. Exp Mol Med,2018,50(1):e431. YANG X,FU Y,HU F,et al.PIK3R3 regulates PPARalpha expression to stimulate fatty acid beta-oxidation and decrease hepatosteatosis[J]. Exp Mol Med,2018,50(1):e431.
7、 PERLA F M,PRELATI M,LAVORATO M,et al.The Role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease[J]. Children (Basel),2017,4(46):1-14. PERLA F M,PRELATI M,LAVORATO M,et al.The Role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease[J]. Children (Basel),2017,4(46):1-14.
8、 YOUNOSSI Z,ANSTEE QM,MARIETTI M,et al.Global burden of NAFLD and NASH: trends,predictions,risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):11-20. YOUNOSSI Z,ANSTEE QM,MARIETTI M,et al.Global burden of NAFLD and NASH: trends,predictions,risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):11-20.
9、 CHALASANI N,GUO X,LOOMBA R,et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease[J]. Gastroenterol,2010,139(5):1567-1576,1576 e1561-1566. CHALASANI N,GUO X,LOOMBA R,et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease[J]. Gastroenterol,2010,139(5):1567-1576,1576 e1561-1566.
10、 CHALASANI N,YOUNOSSI Z,LAVINE J E,et al.The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association,American Association for the Study of Liver Diseases,and American College of Gastroenterology[J]. Gastroenterol,2012,142(7):1592-1609. CHALASANI N,YOUNOSSI Z,LAVINE J E,et al.The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association,American Association for the Study of Liver Diseases,and American College of Gastroenterology[J]. Gastroenterol,2012,142(7):1592-1609.
